This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tissier, F. Articles by Bertherat, J. Search for Related Content PubMed PubMed Citation Articles by Tissier, F. Articles by Bertherat, J.

Mutations of ß-Catenin in Adrenocortical Tumors: Activation of the Wnt Signaling Pathway Is a Frequent Event in both Benign and Malignant Adrenocortical Tumors

Departments of ¹ Endocrinology and ² Genetics, Development and Molecular Pathology, Institut Cochin, Institut National de la Santé et de la Recherche Médicale U567, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8104, IFR116, René Descartes-Paris 5 University; Departments of ³ Pathology and ⁴ Endocrinology, and ⁵ Oncogenetics Unit, Hopital Cochin, Assistance Publique-Hôpitaux de Paris, René Descartes-Paris 5 University; ⁶ Department of Physiology, Hopital Trousseau, Assistance Publique-Hôpitaux de Paris; and ⁷ COMETE Network, Paris, France

Requests for reprints: Jérôme Bertherat, Service des Maladies Endocriniennes et Métaboliques, Hôpital Cochin, 27 rue du Fg-St-Jacques, 75014, Paris, France. Phone: 15-841-1895; Fax: 14-633-8060; E-mail: jerome.bertherat{at}cch.ap-hop-paris.fr.

Adrenocortical cancer is a rare cancer with a very poor prognosis. The genetic alterations identified to date in adrenocortical tumors are limited. Activating mutations of the Wnt signaling pathway have been observed in more frequent cancers, particularly digestive tract tumors. We investigated whether Wnt pathway activation is involved in adrenocortical tumorigenesis. In a series of 39 adrenocortical tumors, immunohistochemistry revealed abnormal cytoplasmic and/or nuclear accumulation of ß-catenin in 10 of 26 adrenocortical adenomas and in 11 of 13 adrenocortical carcinomas. An activating somatic mutation of the ß-catenin gene was shown in 7 of 26 adrenocortical adenomas and in 4 of 13 adrenocortical carcinomas; these mutations were observed only in adrenocortical tumors with abnormal ß-catenin accumulation and most were point mutations altering the Ser⁴⁵ of exon 3 (in the consensus GSK3-ß/CK1 phosphorylation site). Functional studies showed that the activating Ser⁴⁵ ß-catenin mutation found in the adrenocortical cancer H295R cell line leads to constitutive activation of T-cell factor–dependent transcription. This is the first molecular defect to be reported with the same prevalence in both benign (27%) and malignant (31%) adrenocortical tumors. ß-Catenin mutations are also the most frequent genetic defect currently known in adrenocortical adenomas. In adrenocortical adenomas, ß-catenin alterations are more frequent in nonfunctioning tumors, suggesting that ß-catenin pathway activation might be mostly involved in the development of nonsecreting adrenocortical adenomas and adrenocortical carcinomas. The very frequent and substantial accumulation of ß-catenin in adrenocortical carcinomas suggests that other alterations might also be involved. This finding may contribute to new therapeutic approaches targeting the Wnt pathway in malignant adrenocortical tumors, for which limited medical therapy is available.

This article has been cited by other articles:

				H. Hosogi, S. Nagayama, N. Kanamoto, A. Yoshizawa, T. Suzuki, K. Nakao, and Y. Sakai Biallelic APC Inactivation Was Responsible for Functional Adrenocortical Adenoma in Familial Adenomatous Polyposis with Novel Germline Mutation of the APC Gene: Report of a Case Jpn. J. Clin. Oncol., August 14, 2009; (2009) hyp093v1. [Abstract] [Full Text] [PDF]

				S. Schinner, H. S Willenberg, M. Schott, and W. A Scherbaum Pathophysiological aspects of Wnt-signaling in endocrine disease Eur. J. Endocrinol., May 1, 2009; 160(5): 731 - 737. [Abstract] [Full Text] [PDF]

				A. C. Kim, F. M. Barlaskar, J. H. Heaton, T. Else, V. R. Kelly, K. T. Krill, J. O. Scheys, D. P. Simon, A. Trovato, W.-H. Yang, et al. In Search of Adrenocortical Stem and Progenitor Cells Endocr. Rev., May 1, 2009; 30(3): 241 - 263. [Abstract] [Full Text] [PDF]

				L. Groussin, G. Bonardel, S. Silvera, F. Tissier, J. Coste, G. Abiven, R. Libe, M. Bienvenu, J.-L. Alberini, S. Salenave, et al. 18F-Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Adrenocortical Tumors: A Prospective Study in 77 Operated Patients J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1713 - 1722. [Abstract] [Full Text] [PDF]

				M. Bielinska, H. Parviainen, S. Kiiveri, M. Heikinheimo, and D. B. Wilson REVIEW PAPER: Origin and Molecular Pathology of Adrenocortical Neoplasms Vet. Pathol., March 1, 2009; 46(2): 194 - 210. [Abstract] [Full Text] [PDF]

				C. Rodriguez-Galindo, G. Zambetti, and R. C. Ribeiro Epidemiology, Clinical Characteristics, and Treatment of Childhood Adrenocortical Tumors ASCO Educational Book, January 1, 2009; 2009(1): 625 - 629. [Abstract] [Full Text] [PDF]

				C. B d'Alva, G. Abiven-Lepage, V. Viallon, L. Groussin, M. A. Dugue, X. Bertagna, and J. Bertherat Sex steroids in androgen-secreting adrenocortical tumors: clinical and hormonal features in comparison with non-tumoral causes of androgen excess Eur. J. Endocrinol., November 1, 2008; 159(5): 641 - 647. [Abstract] [Full Text] [PDF]

				S. Gaujoux, F. Tissier, L. Groussin, R. Libe, B. Ragazzon, P. Launay, A. Audebourg, B. Dousset, X. Bertagna, and J. Bertherat Wnt/{beta}-Catenin and 3',5'-Cyclic Adenosine 5'-Monophosphate/Protein Kinase A Signaling Pathways Alterations and Somatic {beta}-Catenin Gene Mutations in the Progression of Adrenocortical Tumors J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4135 - 4140. [Abstract] [Full Text] [PDF]

				M. Rizk-Rabin, G. Assie, F. Rene-Corail, K. Perlemoine, H. Hamzaoui, F. Tissier, M. Lieberherr, X. Bertagna, J. Bertherat, and Z. Bouizar Differential Expression of Parathyroid Hormone-Related Protein in Adrenocortical Tumors: Autocrine/Paracrine Effects on the Growth and Signaling Pathways in H295R Cells Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2275 - 2285. [Abstract] [Full Text] [PDF]

				M. Doghman, J. Cazareth, and E. Lalli The T cell factor/{beta}-Catenin Antagonist PKF115-584 Inhibits Proliferation of Adrenocortical Carcinoma Cells J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3222 - 3225. [Abstract] [Full Text] [PDF]

				A. C. Kim, A. L. Reuter, M. Zubair, T. Else, K. Serecky, N. C. Bingham, G. G. Lavery, K. L. Parker, and G. D. Hammer Targeted disruption of {beta}-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex Development, August 1, 2008; 135(15): 2593 - 2602. [Abstract] [Full Text] [PDF]

				M Volante, C Buttigliero, E Greco, A Berruti, and M Papotti Pathological and molecular features of adrenocortical carcinoma: an update J. Clin. Pathol., July 1, 2008; 61(7): 787 - 793. [Abstract] [Full Text] [PDF]

				R. Libe, A. Fratticci, J. Coste, F. Tissier, A. Horvath, B. Ragazzon, F. Rene-Corail, L. Groussin, X. Bertagna, M. L. Raffin-Sanson, et al. Phosphodiesterase 11A (PDE11A) and Genetic Predisposition to Adrenocortical Tumors Clin. Cancer Res., June 15, 2008; 14(12): 4016 - 4024. [Abstract] [Full Text] [PDF]

				C Vincent-Dejean, L Cazabat, L Groussin, K Perlemoine, G Fumey, F Tissier, X Bertagna, and J Bertherat Identification of a clinically homogenous subgroup of benign cortisol-secreting adrenocortical tumors characterized by alterations of the protein kinase A (PKA) subunits and high PKA activity. Eur. J. Endocrinol., June 1, 2008; 158(6): 829 - 839. [Abstract] [Full Text] [PDF]

				P. S. H. Soon, K. L. McDonald, B. G. Robinson, and S. B. Sidhu Molecular Markers and the Pathogenesis of Adrenocortical Cancer Oncologist, May 1, 2008; 13(5): 548 - 561. [Abstract] [Full Text] [PDF]

				A Stigliano, L Cerquetti, M Borro, G Gentile, B Bucci, S Misiti, P Piergrossi, E Brunetti, M Simmaco, and V Toscano Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane Endocr. Relat. Cancer, March 1, 2008; 15(1): 1 - 10. [Abstract] [Full Text] [PDF]

				R. Libe, A. Fratticci, and J. Bertherat Adrenocortical cancer: pathophysiology and clinical management Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28. [Abstract] [Full Text] [PDF]

				R. Libe, L. Groussin, F. Tissier, C. Elie, F. Rene-Corail, A. Fratticci, E. Jullian, P. Beck-Peccoz, X. Bertagna, C. Gicquel, et al. Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity Clin. Cancer Res., February 1, 2007; 13(3): 844 - 850. [Abstract] [Full Text] [PDF]

				G. Abiven, J. Coste, L. Groussin, P. Anract, F. Tissier, P. Legmann, B. Dousset, X. Bertagna, and J. Bertherat Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2650 - 2655. [Abstract] [Full Text] [PDF]